据证券之星公开数据整理，近期康泰生物（300601）发布2025年中报。根据财报显示，康泰生物增收不 增利。截至本报告期末，公司营业总收入13.92亿元，同比上升15.81%，归母净利润3753.27万元，同比 下降77.3%。按单季度数据看，第二季度营业总收入7.47亿元，同比下降0.47%，第二季度归母净利润 1509.87万元，同比下降86.43%。 本次财报公布的各项数据指标表现一般。其中，毛利率75.95%，同比减9.34%，净利率2.7%，同比减 80.36%，销售费用、管理费用、财务费用总计6.43亿元，三费占营收比46.22%，同比减4.77%，每股净 资产8.14元，同比增0.71%，每股经营性现金流0.07元，同比增31.42%，每股收益0.03元，同比减80.0% 预收款项变动幅度为279.29%,原因:本报告期预收客户租赁款项。 应付职工薪酬变动幅度为-46.43%,原因:本报告期支付上年度计提的年终奖。 一年内到期的非流动负债变动幅度为-86.12%,原因:本报告期归还一年内到期的借款。 财务报表中对有大幅变动的财务项目的原因说明如下： 货币资金变动幅度为-50.05%,原因:本报告 ...

Group 1 - The liquidity of the biotechnology vaccine ETF showed a turnover of 1.21% with a transaction volume of 3.1203 million yuan, and the average daily transaction volume over the past week was 11.3875 million yuan as of May 28 [2] - The biotechnology vaccine ETF closely tracks the CSI Vaccine and Biotechnology Index, which selects no more than 50 companies involved in vaccine research, production, and related biotechnology sectors, reflecting the overall performance of listed companies in this theme [2] - As of April 30, 2025, the top ten weighted stocks in the CSI Vaccine and Biotechnology Index include Wantai Biological Pharmacy, Zhifei Biological Products, and others, accounting for a total of 48.51% of the index [2] Group 2 - The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will take place from May 30 to June 3 in Chicago, showcasing cutting-edge clinical oncology research and treatment technologies [2] - Guotai Junan Securities recently indicated that the vaccine industry is expected to see a significant increase in inventory levels in both halves of 2024, continuing into the first quarter of 2025, influenced by demand fluctuations and channel inventory adjustments [2] - The overall sentiment in the vaccine sector is under pressure due to factors such as centralized procurement policies and regional political issues [2] Group 3 - Guoxin Securities reported that in April 2025, domestic innovative drug NDA/IND applications remained active, with progress in approvals for vaccine products like the Kangle Guardian trivalent HPV vaccine potentially supporting industry sentiment [3]